Do You Actually Need an Implantation Study? How to Make the Call Under ISO 10993-6:2026

One of the most expensive questions in implantable device development is also one of the most frequently answered too quickly: Do we need an implantation study?

The reflex answer — "it's an implant, so yes" — has led to a lot of unnecessary animal studies and a lot of unnecessary cost. The correct answer depends on your specific device, your materials, your existing data, and how you've structured your overall biological evaluation under ISO 10993-1:2025.

ISO 10993-6:2026, the current implantation testing standard, is explicit on this point: animal testing should be avoided unless the required data cannot be obtained by other means. That's the starting premise, not an afterthought.

Here's how to think through the decision rigorously.

The Standard Doesn't Assume You Need a Study

ISO 10993-6:2026 opens with a clear requirement: prior to choosing to pursue implantation studies, consideration shall be given to the type of data required, the appropriate method, and the approach to ensure that data collected covers the concerns for biological reactivity.

Before a study is designed or commissioned, there should be a documented evaluation of whether in vivo implantation testing is actually necessary to address the identified biological risks.

This aligns directly with the risk-based framework in ISO 10993-1:2025. Under that standard, biological testing is conducted only when existing information is insufficient to adequately assess biological risks. The decision sequence runs: characterize the device, identify biological hazards, estimate risks using available information, identify gaps, and then — only if gaps exist that can't be addressed another way — plan testing.

An implantation study is one tool for closing specific data gaps. It is not a mandatory entry on a testing checklist.

What Implantation Testing Actually Evaluates

Understanding what an implantation study does and doesn't tell you is essential for making the right call.

ISO 10993-6:2026 characterizes implantation testing as the evaluation of local effects after implantation: the tissue response to a device or material at the implant site, assessed by gross pathology and histopathology. The study compares the tissue response to your test sample against the response to a control material with established clinical acceptability.

Local effects include:

Acute and chronic inflammation — characterized by the types and quantity of inflammatory cells (polymorphonuclear cells, lymphocytes, plasma cells, macrophages, multinucleated giant cells) present in peri-implant tissue

Fibrous encapsulation — the formation and thickness of the fibrous capsule around the implant

Necrosis — the extent of tissue death at or near the implant site

Neovascularization and fibrosis — tissue changes associated with healing and chronic response

Degradation effects — for absorbable materials, the tissue response as degradation proceeds

Implantation testing does not evaluate systemic toxicity, carcinogenicity, genotoxicity, or reproductive toxicity. Those endpoints are addressed by other parts of the ISO 10993 series and, critically, can often be addressed through chemical characterization and toxicological risk assessment without animal testing at all.

When Existing Information Can Close the Gap

Before concluding that an implantation study is required, a thorough review of existing information should be conducted. ISO 10993-1:2025 establishes a hierarchy: material information comes first, then literature data, then chemical characterization, then existing biological test data.

For implantation specifically, several categories of existing information can address local tissue response concerns without additional in vivo testing:

Biological equivalence to a predicate device. If your device uses the same materials, manufacturing processes, sterilization, and configuration as a predicate device with established biocompatibility, and you can demonstrate that equivalence meets the standard's definition, existing implantation data from the predicate may be sufficient. The 2025 edition of ISO 10993-1 defines biological equivalence clearly and requires documented justification for the claim — it's not simply asserting that two devices are "similar."

History of safe clinical use. For materials with well-documented clinical use in comparable contact applications and durations, existing post-market data and literature can support local tissue safety conclusions. The extent to which this applies depends on how closely the prior use matches your specific device and intended application.

Chemical characterization and toxicological risk assessment. Chemical characterization identifies and quantifies the constituents that can be released from your device into tissue. For many local tissue concerns driven by chemical constituents, rather than by the physical form or configuration of the device, a well-conducted chemical characterization with toxicological risk assessment can provide the data needed to evaluate biological risk without in vivo testing.

Chemical characterization has limits when it comes to local tissue endpoints. Toxicological databases don't cover local tissue effects as well as they cover systemic ones, and physical characteristics — surface texture, porosity, particle size, configuration — can drive tissue responses that no amount of chemical data is going to predict. That said, it's still worth working through what your chemistry data can support before you jump straight to an animal study. 

In vitro testing for specific endpoints. In vitro cytotoxicity testing under ISO 10993-5 and irritation testing under ISO 10993-23 can address specific local biological endpoints without animal studies. When in vitro results are negative and no other risk factors are identified, they can support conclusions that additional in vivo evaluation is not warranted.

When an Implantation Study Is Required

After evaluating existing information, the question becomes: what gaps remain?

An implantation study is typically required when:

Novel materials or novel material combinations are used for which there is no established biocompatibility history in the specific tissue contact application. The more novel the material — new polymers, new surface treatments, new combinations — the less existing data can substitute for direct tissue response evaluation.

The physical form drives tissue response concerns that existing chemistry data can't address. Porous materials, textured surfaces, absorbable scaffolds, and particulate-releasing materials all present tissue interaction scenarios where in vivo evaluation is often necessary because the physical characteristics of the device — not just its chemical constituents — determine the tissue response.

Absorbable or degradable materials are used, and the degradation profile and associated tissue response have not been characterized. ISO 10993-6:2026 has detailed requirements for absorbable materials that include time points spanning early, mid, and late degradation stages, often extending through or beyond complete absorption. Existing data for similar absorbable materials in different applications is unlikely to substitute.

Existing biological testing data doesn't match your device. If available data comes from a different contact site, a different duration category, a different material configuration, or was generated under a prior version of the standard with different requirements, its relevance to your current device needs to be carefully evaluated. Where relevance cannot be established, new testing is likely required.

Post-market surveillance has identified concerns with similar devices or materials that warrant prospective evaluation.

The Gap Analysis Is the Decision

Under ISO 10993-1:2025, the mechanism for making this determination formally is the biological risk analysis and gap analysis. You document the biological hazards you've identified, the existing information you've reviewed, what that information can and cannot address, and where data gaps remain. The gap analysis is what tells you whether implantation testing is required and, if so, what specific data it needs to provide.

This documented process is not just good scientific practice, it's what FDA reviewers evaluate when they assess your biocompatibility data package. The question isn't whether you did an implantation study; it's whether you made the right decision about whether to conduct one, and whether you can show your reasoning.

A well-documented conclusion that existing information is sufficient to address local tissue concerns, with clear scientific justification, is a defensible regulatory position. So is a well-designed implantation study with clear rationale for why it was needed. What doesn't hold up is a study conducted reflexively without consideration of whether it was necessary, or a decision not to test without documentation of the existing information reviewed and why it was sufficient.

What Good Study Planning Looks Like When Testing Is Required

When the gap analysis concludes that implantation testing is needed, the planning decisions that follow carry significant regulatory weight. ISO 10993-6:2026 requires that studies be planned and documented in detail before they begin, including the selected test methods, test samples, test animals, implantation sites, test duration, measurement frequencies, assessment methods, and evaluation criteria.

The standard is also clear that the implantation site must match the intended clinical use. Subcutaneous tissue, muscle, bone, and neural tissue each have dedicated normative annexes with specific requirements. If the study is conducted in a tissue that doesn't reflect clinical use, the resulting data may not support the conclusions you need and the justification for the site choice must be documented regardless.

What This Means in Practice

The decision of whether to conduct an implantation study sits at the intersection of scientific judgment, regulatory strategy, and resource allocation. Getting it right requires honest assessment of what your existing information can and cannot support, a clear understanding of what implantation testing does and doesn't provide, and the documentation discipline to show your reasoning.

Getting it wrong in either direction has costs. An unnecessary study consumes time and budget, uses animals for data you didn't need, and can actually create regulatory complications if the results require interpretation. A missing study, or one that's poorly designed for the question it needs to answer, creates data gaps that surface during FDA review at the worst possible time.

Strategic Biocompatibility Consulting for Implantable Medical Devices

Deciding whether an implantation study is required, and designing it correctly when it is, requires specialized knowledge of ISO 10993-6:2026 requirements, ISO 10993-1:2025's risk-based framework, and how FDA evaluates biocompatibility data packages for implantable devices.

At JL Tox Consulting, we help medical device manufacturers and CROs make defensible biocompatibility decisions that are grounded in science and built for regulatory review.

Our implantable device biocompatibility services include:

• Biological evaluation planning under ISO 10993-1:2025, including gap analysis to determine whether implantation testing is required

• Scientific justification documentation for decisions to conduct, limit, or waive implantation testing

• Implantation study design aligned with ISO 10993-6:2026 when testing is required

• Chemical characterization strategy and toxicological risk assessment to address biological endpoints without unnecessary animal studies

• Biological equivalence assessment for devices with predicate comparators

• FDA submission support for 510(k), PMA, and De Novo applications requiring biocompatibility data packages

• Deficiency response preparation addressing FDA questions about implantation testing decisions

With over a decade of specialized experience in medical device biocompatibility and FDA regulatory submissions, Dr. James Lyons and the JL Tox team provide the toxicological and regulatory expertise needed to develop biocompatibility strategies that are scientifically sound and regulatorily defensible.

Contact JL Tox Consulting to determine the right implantation testing strategy for your device:

Email: info@JLTox.com

Phone: (877) 899-6568